RiverVest

Feb 16, 2010
Urology Study Shows Reduced Side Effects From Radiation For Prostate Cancer With Calypso Medical’s Tumor Tracking Technology
Jan 05, 2010
Excaliard Initiates Phase 2 Trials in U.S. For Its Skin Scarring Drug, EXC 001
Jan 05, 2010
CyDex Pharmaceuticals Receives a Key U.S. Patent for Composition of Matter and Process of Manufacturing High-Purity Captisol®
Dec 15, 2009
Accumetrics Closes 2009 with Positive Outlook

RiverVest Venture Partners® is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit.

Case Study:

RiverVest’s Founding Role Launches Device Company

When medical device inventor Lixiao Wang, Ph.D., called on RiverVest Managing Director Dennis Wahr, M.D., to help develop a drug-coated balloon catheter based on his patent-pending technology, he was looking for leadership in addition to funding. Read more >

“We are making rapid progress, with clinical trials expected to begin in 2009.” — Dennis Wahr, M.D., President and CEO Lutonix, Inc., and RiverVest Venture Partner